Supernus Pharmaceuticals, Inc.

SUPN

US8684591089

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
30.07 ^USD	+2.59%		+2.28%	+3.90%

Apr. 08	Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready	DJ
Apr. 08	Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket	MT

Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024

February 27, 2024 at 04:15 pm EST

Supernus Pharmaceuticals, Inc. provided earnings guidance for the year 2024. For the year, the company expects total revenues (includes approximately $125 - $135 million of Trokendi XR and Oxtellar XR) of $580 million - $620 million, and Operating loss of $30 million - $0 million.

Latest news about Supernus Pharmaceuticals, Inc.

Supernus Pharmaceuticals Shares Slip 6.9% After FDA Says Drug Application Not Ready	Apr. 08	DJ
Supernus' Investigational Drug Application for Parkinson's Apomorphine Pump Suffers FDA Setback; Shares Fall Premarket	Apr. 08	MT
Supernus Pharmaceuticals, Inc. Announces a Regulatory Update for SPN-830	Apr. 08	CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease	Apr. 08	RE
Supernus Pharmaceuticals Insider Sold Shares Worth $511,677, According to a Recent SEC Filing	Mar. 25	MT
Supernus Pharmaceuticals Insider Sold Shares Worth $436,573, According to a Recent SEC Filing	Mar. 21	MT
Transcript : Supernus Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:35 PM	Mar. 13
Piper Sandler Cuts Price Target on Supernus Pharmaceuticals to $41 From $45, Maintains Overweight Rating	Feb. 28	MT
Transcript : Supernus Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 27, 2024	Feb. 27
Supernus Pharmaceuticals, Inc. Announces Intangible Asset Impairment Charges for the Quarter Ended December 31, 2023	Feb. 27	CI
Supernus Pharmaceuticals, Inc. Provides Earnings Guidance for the Year 2024	Feb. 27	CI
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Posts Q4 Revenue $164.3M, vs. Street Est of $155M	Feb. 27	MT
Supernus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Supernus Pharmaceuticals, Inc. Announces Executive Changes	Feb. 21	CI
Supernus Says US District Court Rules Torrent Pharmaceuticals Infringed Patents	Feb. 05	MT
Supernus Pharmaceuticals Signs License Deal With Knight Therapeutics for Qelbree in Canada	Dec. 19	MT
Knight Therapeutics Brief: Entering into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree (viloxazine) in Canada	Dec. 19	MT
Knight Therapeutics Enters into Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada	Dec. 19	CI
Knight Therapeutics in Exclusive License Agreement with Supernus Pharmaceuticals for Qelbree in Canada	Dec. 19	MT
US Consumer Advocacy Group Seeks to Strengthen Warnings on Botox Labeling	Dec. 12	MT
US Consumer group seeks stronger warnings on Botox, similar treatments	Dec. 12	RE
Supernus Pharmaceuticals Insider Sold Shares Worth $259,151, According to a Recent SEC Filing	Nov. 17	MT
Transcript : Supernus Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023	Nov. 08
Earnings Flash (SUPN) SUPERNUS PHARMACEUTICALS Reports Q3 Revenue $153.9M, vs. Street Est of $143.4M	Nov. 08	MT

Chart Supernus Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Supernus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinsonâs Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The Company is also developing a range of novel CNS product candidates, including new potential treatments for hypomobility in PD, epilepsy, depression, and other CNS disorders. Its commercial products, including Qelbree (viloxazine), GOCOVRI (amantadine), Oxtellar XR (oxcarbazepine), Trokendi XR (topiramate), APOKYN (apomorphine hydrochloride injection) and others. Qelbree (viloxazine) is a novel non-stimulant product indicated for the treatment of ADHD.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Supernus Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

30.07 USD

Average target price

40.33 USD

Spread / Average Target

+34.13%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

	1st Jan change	Capi.
SUPERNUS PHARMACEUTICALS, INC.	+3.90%	1.65B
MERCK KGAA	+5.31%	70.44B
KYOWA KIRIN CO. LTD.	+10.97%	8.94B
SK BIOPHARMACEUTICALS CO., LTD.	-16.83%	4.75B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	+43.48%	4.5B
YUHAN CORPORATION	+3.20%	3.85B
INDIVIOR PLC	+18.82%	2.38B
BETTA PHARMACEUTICALS CO., LTD.	-21.36%	2.34B
CHANGCHUN BCHT BIOTECHNOLOGY CO.	-29.67%	2.2B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.	+8.38%	1.96B

Specialty & Advanced Pharmaceuticals